Modern rheumatology case reports · 2026
Progressive macrocytic anaemia over 14 years leading to the diagnosis of VEXAS syndrome in a patient initially diagnosed with adult-onset Still's disease.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abe Kazuya, Takahashi Kentaro, Matsuki Ayako, Zaimoku Yoshitaka, Umibe Takeshi
Аннотация
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently recognised autoinflammatory disease caused by somatic mutations in UBA1. Its clinical features include recurrent fever, systemic inflammation affecting multiple organs, and progressive haematologic abnormalities such as macrocytic anaemia. Because these manifestations overlap with other autoinflammatory diseases, including adult-onset Still's disease, the diagnosis can be challenging. In this case report, we describe a patient initially diagnosed with adult-onset Still's disease who was ultimately found to have VEXAS syndrome 5 years later due to progressive macrocytic anaemia. The patient developed recurrent fever and skin rash but did not have macrocytic anaemia at onset. Over the subsequent 5 years, his mean corpuscular volume progressively increased. Bone marrow biopsy revealed no evidence of malignancy but showed vacuoles in myeloid and erythroid progenitor cells. Based on these findings, VEXAS syndrome was suspected, and UBA1 testing identified the pathogenic p.Met41Thr variant, thereby confirming the diagnosis. This case highlights that macrocytic anaemia may not be present in the early phase of VEXAS syndrome. In patients diagnosed with adult-onset Still's disease who later develop or progressively worsen macrocytic anaemia, clinicians should consider VEXAS syndrome and perform UBA1 variant testing.